Vaccines for Leukemia
Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best services for vaccine development against leukemia and guarantee the finest results for our customers all over the world.
Leukemia is a type of cancer arising from the bone marrow and causes a large number of abnormal white blood cells. These white blood cells are not fully developed and are known as blast cells or leukemic cells. The exact cause of leukemia is unknown. It is believed that a combination of genetic and environmental (non-genetic) factors play a role in leukemia. Risk factors may include a family history of leukemia, ionizing radiation, smoking, certain chemicals like benzene, prior chemotherapy and Down's syndrome. Symptoms may include fever, bruising and bleeding, feeling tired and increased risk of infection. These symptoms are caused by the lack of normal blood cells. Diagnosis is usually done by blood test or bone marrow biopsy. Treatment may involve some combination of chemotherapy, radiation therapy, targeted therapy and bone marrow transplantation, as well as supportive care and palliative care as needed.
Types of Leukemia
- Acute lymphoblastic leukemia (ALL)
- Acute myeloid leukemia (AML)
- Chronic lymphocytic leukemia (CLL)
- Chronic myeloid leukemia (CML)
Therapeutic Vaccines for Leukemia
Myeloid forms of leukemia would seem to be an ideal disease for investigators wishing to develop targeted immunotherapy because the leukemia is derived from antigen-presenting cells and because clinical data have demonstrated that there is potent T-cell immunity to chronic myeloid leukemia when donor lymphocyte infusions are used to treat relapse after transplantation. Various candidate antigens have been identified in leukemia immunity. For instance, tissue-restricted minor histocompatibility antigens (mHAs) that are derived from proteins expressed only in hematopoietic tissue have been shown to be the targets of alloreactive T cells. These mHAs often result from polymorphic differences between donor and recipient in the coding regions of peptide antigens that bind within the groove of MHC molecules and are recognized by donor T cells.
Creative Biolabs offers vaccine development strategies for peptide vaccine antigens, including PR1, WT-1, BCR-ABL and more. These antigens seem to be promising for little or no toxicity. Patients who experience clinical benefit are those with minimal disease who may have an intact T-cell repertoire with the potential to recognize the peptide antigen/MHC. This observation may in part explain why peptide vaccination of leukemia may hold greater potential than similar vaccine strategies for solid tumors. In the future, combination therapy with targeted small molecules, viewed mostly as drugs that target critical molecular pathways in malignant cells, may also include vaccine antigens.
Creative Biolabs is a leader in the field of vaccine development and has focused on the cancer vaccines for years. We have experts who are able to help you with the vaccine development for leukemia. If you are interested in our services, please contact us for more details.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
